4 Healthcare Stock Stories Making Wednesday Waves

Pfizer Inc. (NYSE:PFE): Closing price $28.44

On Wednesday, Pfizer reported that its pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), won European approval for an expanded indication to include adults aged 18 to 49 years, for active immunization for the prevention of invasive disease caused by
vaccine-type Streptococcus pneumoniae. The drug was previously okayed in the European Union for use in infants, young children and adolescents aged 6 weeks to 17 years, together with adults 50 years of age and older, and is now the sole pneumococcal vaccine in the EU that affords protection against invasive disease from infancy through adulthood. The European Commission was the first to approve Prevenar 13 to offer protection against invasive disease at every stage of life.

Are these stocks a buy or sell? Let us help you decide. PFE

Array BioPharma Inc. (NASDAQ:ARRY): Closing price $5.15

Array BioPharma and the biopharmaceutical firm Loxo Oncology, Inc., which was recently established and funded by Aisling Capital, have announced a multi-year license and collaboration arrangement for an Array-invented preclinical development candidate and related intellectual property. What is more, Loxo and Array will work jointly to discover and develop small molecule drugs for novel oncology targets on which they mutually agree. Pursuant to the terms of the agreement, Loxo will fund Array’s preclinical research, allowing access to Array’s discovery platform and scientists, and will be responsible for target selection and running clinical trials.  In addition, Array is eligible to receive as much as $434 million in milestone payments, and to receive royalties on sales of any resulting drugs.

Are these stocks a buy or sell? Let us help you decide. ARRY

General Electric Co. (NYSE:GE): Closing price $23.54

GE Healthcare announced Wednesday the intro by GE Healthcare’s Clarient Diagnostic Services of the first lab developed test employing MultiOmyx, a ground-breaking new pathology platform that uses proprietary methodology through which to assess multiple proteins from a single-tissue section at a single-cell level. This test is presently available, and offers an aid to a pathologist’s diagnosis of CD30-positive lymphoma cases having difficult morphology or otherwise insufficient tissue so as to adequately evaluate the case.

Are these stocks a buy or sell? Let us help you decide. GE

Celldex Therapeutics, Inc. (NASDAQ:CLDX): Closing price $19.95

Celldex announced Wednesday that the United States Patent and Trademark Office has issued US Patent No: 8,481,029 entitled Human immune therapies using a CD27 agonist alone or in combination with other immune modulators, which broadly supports the firm’s product candidate CDX-1127. CD27, which is a signaling molecule expressed on T lymphocytes, can be effectively manipulated using activating antibodies to induce potent anti-tumor responses and, because of the restricted expression and regulation of CD27, could result in less toxicity overcoming a key barrier that other targets in this class have faced. CDX-1127 is a fully human monoclonal antibody that targets CD27, and is now in Phase 1 clinical development for the treatment of solid tumors and hematologic malignancies.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CLDX

Don’t Miss: Pfizer’s Hit Vaccine Gets a New Market.